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MINIREVIEWS

Is it time to replace propranolol with carvedilol for portal
hypertension?
Shahab Abid, Saadat Ali, Muhammad Asif Baig, Anam Akbar Waheed
heart failure. Whether the same effect extends to its
potency in the reduction of portal venous pressures
is a topic of on-going debate. The aim of this review
is to compare the hemodynamic and clinical effects
of carvedilol with propranolol, and attempt assess
whether carvedilol can be used instead of propranolol in
patients with cirrhosis. Carvedilol is a promising agent
among the beta blockers of recent time that has shown
significant effects in portal hypertension hemodynamics.
It has also demonstrated an effective profile in its
clinical application specifically for the prevention of
variceal bleeding. Carvedilol has more potent desired
physiological effects when compared to Propranolol.
However, it is uncertain at the present juncture whether
the improvement in hemodynamics also translates into a
decreased rate of disease progression and complications
when compared to propranolol. Currently Carvedilol
shows promise as a therapy for portal hypertension but
more clinical trials need to be carried out before we can
consider it as a superior option and a replacement for
propranolol.
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Core tip: Carvedilol is a promising agent among the
beta blockers of recent time that has shown significant
effects in portal hypertension hemodynamics. For
primary prophylaxis of variceal bleeding, the effects
of carvedilol were compared to band ligation in a few
trials and showed some promise, but there has been no
comparison with propranolol. Patients not responding to
propranolol have shown clinical response to carvedilol,
opening a new window of clinical application. For
secondary prophylaxis of variceal bleeding, carvedilol
has been shown to be effective. However no head-tohead trials comparing propranolol and carvedilol for
variceal re-bleeding were found in literature.

Abstract
Beta-adrenergic receptor antagonists (β-blockers) have
been well established for use in portal hypertension
for more than three decades. Different Non-selective
β-blockers like propranolol, nadolol, timolol, atenolol,
metoprolol and carvedilol have been in clinical practice
in patients with cirrhosis. Carvedilol has proven 2-4
times more potent than propranolol as a beta-receptor
blocker in trials conducted testing its efficacy for
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was the first, most widely studied NSBB and mainstr
eam for treatment of portal hypertension. Carvedilol
is a nonselective beta-blocker with intrinsic antialpha1-adrenergic activity. It has been a relatively
newer addition to the NSBBs, in the arena of portal
hypertension and has demonstrated promising results
in terms of clinical outcomes.
Carvedilol has proven 2-4 times more potent
than propranolol as a beta-receptor blocker in trials
[15]
conducted testing its efficacy for heart failure .
Whether the same effect extends to its potency in
the reduction of portal venous pressures is a topic of
ongoing debate.
The aim of this article is to compare the hemody
namic and clinical effects of carvedilol with propranolol,
and attempt assess whether carvedilol can be used
instead of propranolol in patients with cirrhosis.
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INTRODUCTION
th

Liver cirrhosis remains the 12 leading cause of
death worldwide according to estimates by the Global
[1]
Burden of Disease Study . Portal hypertension is an
inevitable consequence of cirrhosis and underlies most
of its complications like: variceal bleeding, ascites
[2]
and hepatic encephalopathy . Portal hypertension is
characterised by a pathologic increase in the portal
pressure gradient (the pressure difference between
the portal vein and the hepatic veins) y greater than
5 mmHg. This causes the creation of porto-systemic
collaterals leading to shunting of portal blood to the
systemic circulation, bypassing the liver parenchyma.
It has been shown that therapeutic reduction in portal
pressure has been shown to improve clinical outcomes
and reduces the incidence of recurrent haemorrhage,
[3-5]
ascites, encephalopathy, and death .
Beta-adrenergic receptor antagonists (β-blockers)
have been well established for use in portal hyper
tension for more than three decades. Non-selective
β-blockers (NSBB) have been widely utilized since
1980, when the first article on their role in portal
[6]
hypertension was published by Lebrec et al . Portal
hypertension results from fibrosis or regenerative
nodules in the liver parenchyma increasing resistance
to flow and causing mechanical obstruction; contraction
of sinusoidal and perisinusoidal contractile cells
(stellate cells and vascular smooth muscle cells) with
intrahepatic imbalance between vasoconstrictors (such
as endothelin 1 and angiotensin) and vasodilators; and
splanchnic vasodilatation in secondary to a relatively
ischemic liver or extrahepatic excess of NO, with sGC[7]
PKG signalling and smooth muscle cell relaxation
(Figure 1).
NSBB have a dual mode of action decrease portal
pressure, i.e., reduction of cardiac output and splanchnic
blood flow by β-1 receptor blockade, and β-2 receptor
blockade, resulting in splanchnic vasoconstriction cau
[7]
sed by unopposed effect of alpha 1 receptors . NSBBs
have been proven to decrease incidence of bleeding
(primary prophylaxis) and re-bleeding (secondary
[8-11]
prophylaxis) from esophageal varices
. It has been
demonstrated that they also prevent bleeding from
portal hypertensive gastropathy and development of
[4,12,13]
spontaneous bacterial peritonitis
. Due to their
widely diverse effects in patients with cirrhosis and
widespread use, they have been dubbed as “aspirin” in
[14]
clinical hepatology .
Different NSBBs like propranolol, nadolol, timolol,
atenolol, metoprolol and carvedilol have been in
clinical practice in patients with cirrhosis. Propranolol

WJGE|www.wjgnet.com

HEMODYNAMIC EFFECTS
To achieve successful protection against gastrointestinal
bleeding, the portal pressure [usually measured as
the hepatic venous pressure gradient (HVPG)] has to
be decreased to ≤ 12 mmHg or by 20% of baseline
[16]
values . Long-term follow-up of cirrhotic on beta
blockers has shown that decrease of HVPG of above
mentioned values results in lesser risk of developing
variceal bleeding, ascites, spontaneous bacterial peri
tonitis (SBP), hepatorenal syndrome and hepatic
[4]
encephalopathy .
Comparison of carvedilol to propranolol for portal
hypertension was made in a recent systematic review
with meta-analysis which included five head-to-head
[17-22]
randomised trials
. This analysis favored carvedilol
against propranolol, in terms of: (1) acute effects on
reduction in HVPG [mean weighted difference in %
of reduction in hepatic vein pressure gradient; -7.70
(95%CI: -12.40--3.00)]; (2) long term effects [mean
weighted difference in % of reduction in hepatic vein
pressure gradient was -6.81 (95%CI: -11.35--2.26)];
and (3) overall effects [(mean weighted difference in
% of reduction in hepatic vein pressure gradient -7.24
(95%CI: -10.50--3.97)].
Additionally the same metaanalysis showed that
Carvedilol had a lower relative risk of failure to achieve
hemodynamic response than propranolol. The number
of patients who achieved a reduction in HVPG to ≥
20% or to ≤ 12 mmHg was reported in 4 of the 5
studies and was also markedly higher with carvedilol vs
propranolol (57/94 vs 33/87). However, this favourable
difference for carvedilol did not reach statistical
significance.
Carvedilol caused more reduction in arterial blood
pressure resulting in orthostatic hypotension as
compared to propranolol. Propranolol caused a - 6.66
mmHg (95%CI: -10.17--3.15) mean reduction in
arterial pressure whereas carvedilol caused a mean
reduction of -10.40 (95%CI: -13.9--6.9). The reduction
in mean arterial pressure was found to be significant
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Figure 1 Pathogenesis of portal hypertension.

with both drugs, but the degree of reduction was in the
order of one-third more with carvedilol compared to
[17]
propranolol (Figure 2).
Therefore carvedilol has been shown to be superior
to propranolol in causing of acute, long-term and overall
reduction of the hepatic venous pressure gradient, i.e.,
portal venous pressure. The proportion of patients who
demonstrated an adequate response is also higher for
carvedilol.
Although the translation of these effects in terms
of clinical benefit of reduced gastrointestinal bleeding
events is significant, these changes in hemodynamic
parameters come at the cost of orthostatic hypotension
and fluid retention including ascites, with the use of
carvedilol. However carvedilol can be a safe alternative
in patients who are not hypotensive. In addition car
vedilol has achieved significant hemodynamic response
in more than half of the patients who were resistant to
[23]
propranolol .

variceal development. To-date there were no studies
using carvedilol for pre-primary prophylaxis.
Due to lack of any demonstrated clinical benefits of
β-blockers in patients with portal hypertension without
varices and adverse effects of these medications,
none of the current guidelines (including Baveno V
[2]
[29]
[30]
consensus , AASLD , and EASL/AASLD consensus )
recommend their use for pre-primary prophylaxis.
Primary prophylaxis: NSBB are recommended for
use in primary prevention of variceal bleeding, as they
have been associated with decrease in incidence of first
[2]
bleeding episode and mortality benefits .
A meta-analysis of published randomised controlled
trials on primary prophylaxis including 1859 patients,
revealed pooled risk difference of 11% in incidence
of variceal bleeding with use of propranolol against
[31]
[32]
controls . In another meta-analysis, D’Amico et al
demonstrated that in patients with varices of any size,
β-blockers reduced the risk of a first bleeding episode
from 25% to 15% within 2 years. The absolute risk
difference was 9% (15% vs 24%) as compared to
placebo. Moreover, the absolute risk reduction in
[32]
mortality was found to be 4% (from 27% to 23%) .
Another meta-analyses has reported the usage of
Beta blockers as primary prophylaxis to be associated
with a 40% reduction in bleeding risk and a trend
[33]
towards improved survival . In a double-blind rando
mised trial, the Boston-New Haven-Barcelona Portal
Hypertension Study Group compared propranolol with
placebo for primary prophylaxis. There was significant
difference in incidence of bleeding between the study
groups favouring propranolol (incidence of bleeding
4% vs 22%; P ≤ 0.01) during a mean follow-up of 16
mo. However there was no difference in mortality rates
[34]
between the two groups .
Propranolol has been compared to esophageal
band ligation (EBL) in terms of bleeding prevention

CLINICAL EFFECTS
Variceal bleeding

Pre-primary prophylaxis: Prevention of development
of varices in patients with portal hypertension is known
as pre-primary prophylaxis. Experimental models
of portal hypertension have shown that B-Blockers
[24,25]
delay the development of collaterals
. Escorsell et
[26]
al
demonstrated that administration of β-blockers
(timolol) to patients without varices caused a greater
reduction in portal pressure than the reduction seen
[26]
in patients with varices . However this effect of use
of timolol did not translate into prevention of variceal
formation and variceal hemorrhage in a randomised
[27]
study by Groszmann et al
which compared timolol
with placebo in patients without varices. The study
[28]
by Calés et al
using propranolol, for pre-primary
prophylaxis did not show clinical benefit in terms of
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Figure 2 Hemodynamic effect of carvedilol compared to propranolol (Data from ref.[19]). HVPG: Hepatic venous pressure gradient.

and mortality reduction in patients with cirrhosis in
several randomised controlled trials. A meta-analysis of
sixteen randomised controlled trials found EBL causing
significant reduction of the risk of first variceal bleeding
compared to propranolol (relative risk difference 9.2%,
95%CI: 5.2%-13.1%, and POR 0.5, 95%CI: 0.37–
0.68). However there was no statistically significant
difference in Mortality between the two groups (POR
0.94, 95%CI: 0.70-1.28). On average, 3 endoscopic
sessions were required to eradicate varices and at least
33 endoscopic procedures were needed to prevent one
[35]
bleeding episode as compared with NSBBs . However
as NSBB are cheap, as haemodynamic monitoring is
[36]
not required .
In a randomized control trial, Carvedilol has been
compared with EBL and showed a significantly lower
rate of first variceal bleeding (with minor adverse
effects) in patients taking carvedilol 12.5 mg daily
compared with EBL (10% vs 23%, HR = 0.41, 95%CI:
[37]
0.19-0.96) . The lowest dose of carvedilol tested
in this trial was 12.5 mg, which is known to cause
a smaller reduction in HVPG than to actually cause
prevention of first bleeding episode. So the results of
this study need to be interpreted after considering its
[38]
limitations .
Another randomised controlled trial by Shah et
[39]
al
reported that both EBL and carvedilol groups had
comparable variceal bleeding rates (8.5% vs 6.9%),
bleeding related mortality (4.6% vs 4.9%) and overall
[39]
mortality (12.8% vs 19.5%) respectively . Although
the study was underpowered, the authors suspect that
carvedilol is not superior to EBL for primary prophylaxis
of varices.
Use of carvedilol has been found to cause reduction
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of HVPG in patients failing to respond to propranolol,
thus leading to lesser bleeding episodes in this group
of patients. Bleeding rates followed up for 2 years were
11% with propranolol vs 5% with carvedilol and 25%
[23]
with EBL (P = 0.0429) . We did not find any studies
comparing propranolol with carvedilol head-to-head for
primary prevention.
Secondary prophylaxis: Secondary prophylaxis is
prevention of recurrence after index variceal bleeding
episode. The 1-year mortality after an episode of
[11]
variceal bleeding is 40% . Variceal bleeding recurs in
60% at 1-year with 6-wk mortality of 20% for every
[2]
re-bleeding episode . NSBBs have been widely used
for prevention of re-bleeding and have been shown
to decrease the rate of re-bleeding from varices to
42%, as compared to 63% in controls in several meta[32]
analyses . In addition these agents decrease overall
mortality from 27% to 20%, and bleeding related
[40]
mortality .
Carvedilol was compared with combination of nad
olol and isosorbide-5-mononitrate in a randomized
controlled trial in patients who previously had variceal
bleeding. This study demonstrated that after a followup of 30 mo there was no significant difference in
incidence of recurrent upper gastrointestinal bleeding
between carvedilol and combination groups (62% vs
61%; P = 0.90). There was no significant difference
between the Rate of recurrence of variceal bleeding
between the carvedilol and combination groups (51%
[41]
vs 43%; P = 0.46) . Interim analysis of a multicentre
randomised controlled study comparing carvedilol with
endoscopic band ligation for secondary prevention
of variceal bleeding, demonstrated no significant
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Figure 3 Current evidence about carvedilol and propranolol as prophylactic therapy.
[43]

difference between the groups in re-bleeding rates
(37.5% vs 29%; P = 0.72). However the patients in
carvedilol group had lower 1-year mortality rates as
[42]
compared to EBL group (25% vs 51.6%; P = 0.058) .
[8]
The pioneer trial by Pagliaro et al demonstrated
that propranolol was effective in decreasing the in
cidence of variceal re-bleeding when compared to
controls. A comprehensive meta-analysis of 12 rand
omised controlled trials for secondary prophylaxis
of variceal bleeding showed that, use of β-blockers
(11 using propranolol) was associated with increase
in mean percentage of patients with no re-bleeding
(21% mean improvement rate, 95%CI: 10%-32%,
P < 0.001), the mean percentage of patients with no
variceal re-bleeding (20% mean improvement rate,
95%CI: 11%-28%, P < 0.001), the mean survival rate
(5.4% mean improvement rate, 95%CI: 0%-11%, P <
0.05, RR = 1.27), the mean percentage of patients free
of bleeding death (7.4%, 95%CI: 2%-13%, P < 0.01,
[40]
RR = 1.50) .
Baveno V consensus guidelines recommend a
combination of β-blockers and variceal band ligation
as the preferred therapy for secondary prophylaxis
because it results in lower re-bleeding rates compared
[2]
[43]
to either therapy alone . Ahmad et al
compared
combination of EBL and propranolol against propranolol
for secondary prevention and found no statistical
difference in re-bleeding (22% vs 38%) and mortality
rates (23% vs 19%) between the groups. However
the incidence of re-bleeding was higher in patients on
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propranolol alone .
Propranolol retains its place as the most widely used
and studied drug for secondary prophylaxis with clear
benefits as compared to placebo and combination with
EBL. The evidence for carvedilol in variceal rebleeding
recurrence is minimal but promising.

Portal gastropathy

Described as mosaic, snake-skin-like appearance of
gastric mucosa with or without red punctuate erythema,
portal hypertensive gastropathy (PHG) is estimated to
[44]
be present in up to 80% of cirrhotic patients . PHG
can cause acute bleeding rarely with an incidence of 3%
in three years, and in 2.5%-30% patients it may result
[45,46]
in chronic insidious bleeding
.
NSBBs have been shown to lower the incidence of
bleeding in acute and chronic forms of haemorrhage
from PHG. One of the earliest randomised controlled
trials using propranolol showed lower haemorrhage
rates, increase in haemoglobin level and an apparent
improvement in the endoscopic appearance of the
[47]
lesion when compared to placebo . Pérez-Ayuso et
[12]
al , in a randomised trial of used propranolol against
no therapy in patients for secondary prophylaxis of
bleeding from PHG. The study demonstrated higher
number of patients remaining free of bleeding with
propranolol in acute (85% vs 20%) and chronic setting
(69% vs 30% at 30 mo). On multivariate analysis, the
sole independent predictor of recurrent haemorrhage
[12]
was the absence of propranolol .
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Although the use of β-blockers for PHG is wide
spread, based upon current evidence strong recom
mendations can’t be made for NSBB for this indication.
We also did not find any studies using carvedilol to
control bleeding from portal gastropathy.

to propranolol (Figure 3).
There have been no clinical trials comparing
carvedilol and propranolol for pre-primary prophylaxis.
For Primary prophylaxis, the effects of Carvedilol have
been compared to Endoscopic band ligation in a few
trials and show some promise, but there has been no
head to head comparison with propranolol. However,
patients not responding to propranolol have shown
clinical response to Carvedilol, opening a new window
of clinical application.
For secondary prophylaxis, carvedilol has been
compared to Beta blockers other than propranolol and
Endoscopic Band Ligation, and seems to be equally
effective. However, the most effective therapy to date
remains a combination of Endoscopic Band Ligation,
and no head to head trials have been conducted
comparing carvedilol with propranolol. Similarly, there
have been no trials exploring the role of carvedilol
in portal hypertensive gastropathy and spontaneous
bacterial peritonitis.
Thus, currently Carvedilol shows promise as a
therapy for portal hypertension but more clinical trials
need to be carried out before we can consider it as a
superior option and a replacement for propranolol.

Spontaneous bacterial peritonitis

NSBBs have been shown to have preventive effect
on development of spontaneous bacterial peritonitis
[13]
in a meta-analysis by Senzolo et al . This analysis
included three randomised controlled trials and
two retrospective studies all using propranolol for
prophylaxis of variceal bleeding, with respect to the
incidence of SBP. Statistically significant difference of
12.1% (P < 0.001) was found in favour of propranolol
in prevention of SBP.
A recently published thorough retrospective analysis
of data from 607 patients with cirrhosis by Mandorfer
[48]
et al
demonstrated no difference in incidence of
SBP between NSBB users and patients who did not.
Occurrence rates of SBP were similar between patients
with and without NSBB treatment. However, NSBB
use was associated with higher transplant-free survival
in patients without SBP and reduced hospitalization
[48]
rates .
[48]
In contrast, Mandorfer et al
demonstrated that
in patients who have developed SBP, NSBB were
associated with hemodynamic compromise and dec
reased blood pressures, reduced transplant free
survival, increased hospitalization rates, and incre
ased incidence of the hepatorenal syndrome and
acute kidney injury. In another study, using a NSBB
(propranolol) in patients with refractory ascites was
found to reduce 1-year survival against those not
using this drug (median survival: 5 mo vs 20 mo res
[49]
pectively) . These results advocate against the use of
NSBB in patients with advanced cirrhosis with ascites
and SBP.
To conclude, the current evidence is variable about
the role of NSBB in decreasing the incidence of SBP.
However they can increase transplant-free survival in
patients without SBP. In cases of advanced cirrhosis
with ascites and the patients who have developed
SBP, their use proves detrimental causing higher rates
of hemodynamic compromise, time of hospitalization
and risks of renal dysfunction. All the studies on
NSBB use for SBP have used propranolol. We did not
find any study about the use of carvedilol in patients
with advanced cirrhosis and SBP, nor a head-to-head
comparison of propranolol and carvedilol in this regard.

REFERENCES
1

CONCLUSION
After reviewing the existing literature, it seems that
Carvedilol has more potent desired physiological effects
when compared to Propranolol. However, it is uncertain
at the present juncture whether the improvement in
hemodynamics also translates into a decreased rate of
disease progression and complications when compared

WJGE|www.wjgnet.com

537

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V,
Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson
HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM,
Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett
D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F,
Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J,
Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun
S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M,
Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH,
Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt
L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD,
Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P,
Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG,
Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E,
Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring
D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy
D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns
N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton
LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M,
Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger
L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R,
Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah
GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C,
Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN,
Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, Omer
SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD,
Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce
K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D,
Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León
FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson
U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS,
Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA,
Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA,
Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang
M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD,
Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez
AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional
mortality from 235 causes of death for 20 age groups in 1990

May 16, 2015|Volume 7|Issue 5|

Abid S et al . Carvedilol vs propranolol for portal hypertension

2

3

4

5

6
7
8

9

10

11
12

13

14

15
16

17

18

and 2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012; 380: 2095-2128 [PMID: 23245604 DOI:
10.1016/S0140-6736(12)61728-0]
de Franchis R. Revising consensus in portal hypertension: report
of the Baveno V consensus workshop on methodology of diagnosis
and therapy in portal hypertension. J Hepatol 2010; 53: 762-768
[PMID: 20638742 DOI: 10.1016/j.jhep.2010.06.004]
Feu F, Bordas JM, Luca A, García-Pagán JC, Escorsell A, Bosch J,
Rodés J. Reduction of variceal pressure by propranolol: comparison
of the effects on portal pressure and azygos blood flow in patients
with cirrhosis. Hepatology 1993; 18: 1082-1089 [PMID: 8225212]
Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J,
Bosch J. Hemodynamic response to pharmacological treatment
of portal hypertension and long-term prognosis of cirrhosis.
Hepatology 2003; 37: 902-908 [PMID: 12668985]
D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein
pressure gradient reduction and prevention of variceal bleeding
in cirrhosis: a systematic review. Gastroenterology 2006; 131:
1611-1624 [PMID: 17101332]
Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol--a
medical treatment for portal hypertension? Lancet 1980; 2: 180-182
[PMID: 6105342]
Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new
developments and controversies. Liver Int 2014; 34: 655-667
[PMID: 24134058 DOI: 10.1111/liv.12360]
Pagliaro L. Lebrec D, Poynard T, Hillon P, Benhamou J-P.
Propranolol for prevention of recurrent gastrointestinal bleeding
in patients with cirrhosis. A controlled study [N Engl J Med 1981;
305: 1371-1374]. J Hepatol 2002; 36: 148-150 [PMID: 11830324]
Pascal JP, Cales P. Propranolol in the prevention of first upper
gastrointestinal tract hemorrhage in patients with cirrhosis of the
liver and esophageal varices. N Engl J Med 1987; 317: 856-861
[PMID: 3306385]
Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L,
Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of
gastrointestinal bleeding in patients with cirrhosis and esophageal
varices. An analysis of data and prognostic factors in 589 patients
from four randomized clinical trials. Franco-Italian Multicenter Study
Group. N Engl J Med 1991; 324: 1532-1538 [PMID: 1674104]
Garcia-Tsao G, Bosch J. Management of varices and variceal
hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-832 [PMID:
20200386 DOI: 10.1056/NEJMra0901512]
Pérez-Ayuso RM, Piqué JM, Bosch J, Panés J, González A, Pérez R,
Rigau J, Quintero E, Valderrama R, Viver J. Propranolol in prevention
of recurrent bleeding from severe portal hypertensive gastropathy in
cirrhosis. Lancet 1991; 337: 1431-1434 [PMID: 1675316]
Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U,
Patch D, Burroughs AK. beta-Blockers protect against spontaneous
bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver
Int 2009; 29: 1189-1193 [PMID: 19508620 DOI: 10.1111/
j.1478-3231.2009.02038.x]
Triantos C, Samonakis D, Thalheimer U, Patch D, Burroughs A.
The relationship between liver function and portal pressure: what
comes first, the chicken or the egg? J Hepatol 2005; 42: 146-147;
author reply 147-148 [PMID: 15629521]
Frishman WH. Carvedilol. N Engl J Med 1998; 339: 1759-1765
[PMID: 9845712]
Feu F, García-Pagán JC, Bosch J, Luca A, Terés J, Escorsell A, Rodés
J. Relation between portal pressure response to pharmacotherapy
and risk of recurrent variceal haemorrhage in patients with cirrhosis.
Lancet 1995; 346: 1056-1059 [PMID: 7564785]
Sinagra E, Perricone G, D’Amico M, Tinè F, D’Amico G.
Systematic review with meta-analysis: the haemodynamic effects
of carvedilol compared with propranolol for portal hypertension
in cirrhosis. Aliment Pharmacol Ther 2014; 39: 557-568 [PMID:
24461301 DOI: 10.1111/apt.12634]
Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC,
de Diego A, Bosch J. Carvedilol, a new nonselective beta-blocker
with intrinsic anti- Alpha1-adrenergic activity, has a greater portal
hypotensive effect than propranolol in patients with cirrhosis.

WJGE|www.wjgnet.com

19

20

21

22

23

24

25

26

27

28

29
30

31
32
33

34

538

Hepatology 1999; 30: 79-83 [PMID: 10385642]
Bañares R, Moitinho E, Matilla A, García-Pagán JC, Lampreave
JL, Piera C, Abraldes JG, De Diego A, Albillos A, Bosch J.
Randomized comparison of long-term carvedilol and propranolol
administration in the treatment of portal hypertension in cirrhosis.
Hepatology 2002; 36: 1367-1373 [PMID: 12447861]
De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D,
Maity AK. Acute and 7-day portal pressure response to carvedilol
and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17:
183-189 [PMID: 11966949]
Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute
administration of carvedilol is more effective than propranolol
plus isosorbide-5-mononitrate in the reduction of portal pressure
in patients with viral cirrhosis. Am J Gastroenterol 2004; 99:
1953-1958 [PMID: 15447755]
Hobolth L, Møller S, Grønbæk H, Roelsgaard K, Bendtsen
F, Feldager Hansen E. Carvedilol or propranolol in portal
hypertension? A randomized comparison. Scand J Gastroenterol
2012; 47: 467-474 [PMID: 22401315 DOI: 10.3109/00365521.201
2.666673]
Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter
M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M.
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic
patients with haemodynamic non-response to propranolol. Gut
2013; 62: 1634-1641 [PMID: 23250049]
Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic
administration of propranolol reduces the severity of portal
hypertension and portal-systemic shunts in conscious portal vein
stenosed rats. J Hepatol 1991; 13: 213-219 [PMID: 1744426]
Sarin SK, Groszmann RJ, Mosca PG, Rojkind M, Stadecker
MJ, Bhatnagar R, Reuben A, Dayal Y. Propranolol ameliorates
the development of portal-systemic shunting in a chronic murine
schistosomiasis model of portal hypertension. J Clin Invest 1991;
87: 1032-1036 [PMID: 1900306]
Escorsell A, Ferayorni L, Bosch J, García-Pagán JC, García-Tsao G,
Grace ND, Rodés J, Groszmann RJ. The portal pressure response to
beta-blockade is greater in cirrhotic patients without varices than in
those with varices. Gastroenterology 1997; 112: 2012-2016 [PMID:
9178694]
Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs
AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff
DS, Gao H, Makuch R. Beta-blockers to prevent gastroesophageal
varices in patients with cirrhosis. N Engl J Med 2005; 353:
2254-2261 [PMID: 16306522]
Calés P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P,
Abergel A, Bichard P, Raymond JM, Canva-Delcambre V, Vetter D,
Valla D, Beauchant M, Hadengue A, Champigneulle B, Pascal JP,
Poynard T, Lebrec D. Lack of effect of propranolol in the prevention
of large oesophageal varices in patients with cirrhosis: a randomized
trial. French-Speaking Club for the Study of Portal Hypertension.
Eur J Gastroenterol Hepatol 1999; 11: 741-745 [PMID: 10445794]
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and
management of gastroesophageal varices and variceal hemorrhage
in cirrhosis. Hepatology 2007; 46: 922-938 [PMID: 17879356]
Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and
variceal bleeding--unresolved issues. Summary of an American
Association for the study of liver diseases and European Association
for the study of the liver single-topic conference. Hepatology 2008;
47: 1764-1772 [PMID: 18435460 DOI: 10.1002/hep.22273]
Cheng JW, Zhu L, Gu MJ, Song ZM. Meta analysis of propranolol
effects on gastrointestinal hemorrhage in cirrhotic patients. World J
Gastroenterol 2003; 9: 1836-1839 [PMID: 12918133]
D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of
portal hypertension: an evidence-based approach. Semin Liver Dis
1999; 19: 475-505 [PMID: 10643630]
Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough
AJ. Primary prophylaxis of variceal bleeding in cirrhosis: a costeffectiveness analysis. Gastroenterology 1997; 112: 473-482 [PMID:
9024301]
Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodés J, Wright

May 16, 2015|Volume 7|Issue 5|

Abid S et al . Carvedilol vs propranolol for portal hypertension

35
36

37

38

39

40

41

42

SC, Matloff DS, Garcia-Tsao G, Fisher RL, Navasa M. Propranolol
in the prevention of the first hemorrhage from esophagogastric
varices: A multicenter, randomized clinical trial. The Boston-New
Haven-Barcelona Portal Hypertension Study Group. Hepatology
1991; 13: 902-912 [PMID: 2029994]
Burroughs AK, Tsochatzis EA, Triantos C. Primary prevention of
variceal haemorrhage: a pharmacological approach. J Hepatol 2010;
52: 946-948 [PMID: 20400198 DOI: 10.1016/j.jhep.2010.02.015]
Triantos CK, Nikolopoulou V, Burroughs AK. Review article:
the therapeutic and prognostic benefit of portal pressure reduction
in cirrhosis. Aliment Pharmacol Ther 2008; 28: 943-952 [PMID:
18627364 DOI: 10.1111/j.1365-2036.2008.03798.x]
Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G,
McAvoy NC, Stanley AJ, Forrest EH, Hislop WS, Mills PR, Hayes
PC. Randomized controlled trial of carvedilol versus variceal band
ligation for the prevention of the first variceal bleed. Hepatology
2009; 50: 825-833 [PMID: 19610055 DOI: 10.1002/hep.23045]
Tsochatzis EA, Triantos CK, Burroughs AK. Gastrointestinal
bleeding: Carvedilol-the best beta-blocker for primary prophylaxis?
Nat Rev Gastroenterol Hepatol 2009; 6: 692-694 [PMID: 19946301
DOI: 10.1038/nrgastro.2009.198]
Shah HA, Azam Z, Rauf J, Abid S, Hamid S, Jafri W, Khalid
A, Ismail FW, Parkash O, Subhan A, Munir SM. Carvedilol vs.
esophageal variceal band ligation in the primary prophylaxis of
variceal hemorrhage: a multicentre randomized controlled trial.
J Hepatol 2014; 60: 757-764 [PMID: 24291366 DOI: 10.1016/
j.jhep.2013.11.019]
Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Betaadrenergic antagonists in the prevention of gastrointestinal
rebleeding in patients with cirrhosis: a meta-analysis. Hepatology
1997; 25: 63-70 [PMID: 8985266]
Lo GH, Chen WC, Wang HM, Yu HC. Randomized, controlled
trial of carvedilol versus nadolol plus isosorbide mononitrate
for the prevention of variceal rebleeding. J Gastroenterol
Hepatol 2012; 27: 1681-1687 [PMID: 22849337 DOI: 10.1111/
j.1440-1746.2012.07244.x]
Stanley AJ, Dickson S, Hayes PC, Forrest EH, Mills PR, Tripathi

43

44

45

46

47
48

49

D, Leithead JA, MacBeth K, Smith L, Gaya DR, Suzuki H, Young
D. Multicentre randomised controlled study comparing carvedilol
with variceal band ligation in the prevention of variceal rebleeding.
J Hepatol 2014; 61: 1014-1019 [PMID: 24953021 DOI: 10.1016/
j.jhep.2014.06.015]
Ahmad I, Khan AA, Alam A, Butt AK, Shafqat F, Sarwar S.
Propranolol, isosorbide mononitrate and endoscopic band ligation alone or in varying combinations for the prevention of esophageal
variceal rebleeding. J Coll Physicians Surg Pak 2009; 19: 283-286
[PMID: 19409159]
Primignani M, Carpinelli L, Preatoni P, Battaglia G, Carta A, Prada
A, Cestari R, Angeli P, Gatta A, Rossi A, Spinzi G, De Franchis R.
Natural history of portal hypertensive gastropathy in patients with
liver cirrhosis. The New Italian Endoscopic Club for the study and
treatment of esophageal varices (NIEC). Gastroenterology 2000;
119: 181-187 [PMID: 10889167]
Sarin SK, Shahi HM, Jain M, Jain AK, Issar SK, Murthy NS.
The natural history of portal hypertensive gastropathy: influence
of variceal eradication. Am J Gastroenterol 2000; 95: 2888-2893
[PMID: 11051364]
Merli M, Nicolini G, Angeloni S, Gentili F, Attili AF, Riggio O. The
natural history of portal hypertensive gastropathy in patients with
liver cirrhosis and mild portal hypertension. Am J Gastroenterol
2004; 99: 1959-1965 [PMID: 15447756]
Hosking SW. Congestive gastropathy in portal hypertension:
variations in prevalence. Hepatology 1989; 10: 257-258 [PMID:
2663698]
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M,
Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, PeckRadosavljevic M, Reiberger T. Nonselective β blockers increase
risk for hepatorenal syndrome and death in patients with cirrhosis
and spontaneous bacterial peritonitis. Gastroenterology 2014; 146:
1680-1690.e1 [PMID: 24631577 DOI: 10.1053/j.gastro.2014.03.005]
Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D,
Moreau R, Lebrec D. Deleterious effects of beta-blockers on
survival in patients with cirrhosis and refractory ascites. Hepatology
2010; 52: 1017-1022 [PMID: 20583214 DOI: 10.1002/hep.23775]
P- Reviewer: Sciarra A S- Editor: Ji FF L- Editor: A
E- Editor: Wu HL

WJGE|www.wjgnet.com

539

May 16, 2015|Volume 7|Issue 5|

Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

© 2015 Baishideng Publishing Group Inc. All rights reserved.

